Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
ACS Chem Biol
2017 Nov 17;1211:2804-2814. doi: 10.1021/acschembio.6b01035.
Show Gene links
Show Anatomy links
Identifying Dysregulated Epigenetic Enzyme Activity in Castrate-Resistant Prostate Cancer Development.
Lee JH, Yang B, Lindahl AJ, Damaschke N, Boersma MD, Huang W, Corey E, Jarrard DF, Denu JM.
???displayArticle.abstract???
There is a tremendous need for novel strategies aimed at directly assessing activities of histone modifiers to probe epigenetic determinants associated with disease progression. Here, we developed a high-throughput peptide microarray assay to identify altered histone lysine (de)acetylation activity in prostate cancer (PCa). This microarray-based activity assay revealed up-regulated histone acetyltransferase (HAT) activity against specific histone H3 sites in a castrate-resistant (CR) PCa cell line compared to its hormone-sensitive (HS) isogenic counterpart. NAD+-dependent deacetylation assays revealed down-regulated sirtuin activity in validated CR lines. Levels of acetyltransferases GCN5, PCAF, CBP, and p300 were unchanged between matched HS and CR cell lines. However, autoacetylation of p300 at K1499, a modification known to enhance HAT activity and a target of deacetylation by SIRT2, was highly elevated in CR cells, while SIRT2 protein level was reduced in CR cells. Interrogation of HS and matched CR xenograft lines reveals that H3K18 hyperacetylation, increased p300 activity, and decreased SIRT2 expression are associated with progression to CR in 8/12 (66%). Tissue microarray analysis revealed that hyperacetylation of H3K18 is a feature of CRPC. Inhibition of p300 results in lower H3K18ac levels and increased expression of androgen receptors. Thus, a novel histone array identifies altered enzyme activities during the progression to CRPC and may be utilized in a personalized medicine approach. Reduced SIRT2 expression and increased p300 activity lead to a concerted mechanism of hyperacetylation at specific histone lysine sites (H3K9, H3K14, and H3K18) in CRPC.
Arnold,
Processing mechanism and substrate selectivity of the core NuA4 histone acetyltransferase complex.
2011, Pubmed
Arnold,
Processing mechanism and substrate selectivity of the core NuA4 histone acetyltransferase complex.
2011,
Pubmed Arrowsmith,
Epigenetic protein families: a new frontier for drug discovery.
2012,
Pubmed Berndsen,
Assays for mechanistic investigations of protein/histone acetyltransferases.
2005,
Pubmed Bianco-Miotto,
Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development.
2010,
Pubmed Black,
The SIRT2 deacetylase regulates autoacetylation of p300.
2008,
Pubmed Britton,
Breaking the histone code with quantitative mass spectrometry.
2011,
Pubmed Cheung,
Synergistic coupling of histone H3 phosphorylation and acetylation in response to epidermal growth factor stimulation.
2000,
Pubmed Choudhary,
The growing landscape of lysine acetylation links metabolism and cell signalling.
2014,
Pubmed Corey,
LuCaP 35: a new model of prostate cancer progression to androgen independence.
2003,
Pubmed Dawson,
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.
2011,
Pubmed Debes,
p300 in prostate cancer proliferation and progression.
2003,
Pubmed Debes,
p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6.
2002,
Pubmed Dryden,
Role for human SIRT2 NAD-dependent deacetylase activity in control of mitotic exit in the cell cycle.
2003,
Pubmed Esteller,
Cancer epigenomics: DNA methylomes and histone-modification maps.
2007,
Pubmed Feldman,
Sirtuin catalysis and regulation.
2012,
Pubmed Finnin,
Structure of the histone deacetylase SIRT2.
2001,
Pubmed Fraga,
Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer.
2005,
Pubmed Gygi,
Correlation between protein and mRNA abundance in yeast.
1999,
Pubmed Ha,
Phosphorylation of the androgen receptor by PIM1 in hormone refractory prostate cancer.
2013,
Pubmed Han,
Acetylation of Sirt2 by p300 attenuates its deacetylase activity.
2008,
Pubmed Hiratsuka,
Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene.
2003,
Pubmed Huang,
A colorful future of quantitative pathology: validation of Vectra technology using chromogenic multiplexed immunohistochemistry and prostate tissue microarrays.
2013,
Pubmed Huang,
Quantitative proteomic analysis of histone modifications.
2015,
Pubmed Inoue,
SIRT2 downregulation confers resistance to microtubule inhibitors by prolonging chronic mitotic arrest.
2009,
Pubmed Inoue,
SIRT2, a tubulin deacetylase, acts to block the entry to chromosome condensation in response to mitotic stress.
2007,
Pubmed Jenuwein,
Translating the histone code.
2001,
Pubmed Karanam,
Kinetic and mass spectrometric analysis of p300 histone acetyltransferase domain autoacetylation.
2006,
Pubmed Kouzarides,
Chromatin modifications and their function.
2007,
Pubmed Leroy,
A quantitative atlas of histone modification signatures from human cancer cells.
2013,
Pubmed Liu,
The structural basis of protein acetylation by the p300/CBP transcriptional coactivator.
2008,
Pubmed Love,
The histone acetyltransferase PCAF regulates p21 transcription through stress-induced acetylation of histone H3.
2012,
Pubmed Luger,
Preparation of nucleosome core particle from recombinant histones.
1999,
Pubmed
,
Xenbase North,
Mitotic regulation of SIRT2 by cyclin-dependent kinase 1-dependent phosphorylation.
2007,
Pubmed Oliver,
Multivalent recognition of histone tails by the PHD fingers of CHD5.
2012,
Pubmed Pandithage,
The regulation of SIRT2 function by cyclin-dependent kinases affects cell motility.
2008,
Pubmed Seligson,
Global histone modification patterns predict risk of prostate cancer recurrence.
2005,
Pubmed Soucek,
Normal and prostate cancer cells display distinct molecular profiles of alpha-tubulin posttranslational modifications.
2006,
Pubmed Stephenson,
Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era.
2009,
Pubmed Stitt,
Why measure enzyme activities in the era of systems biology?
2014,
Pubmed Su,
ChIP-less analysis of chromatin states.
2014,
Pubmed Thalmann,
LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis.
2000,
Pubmed Thalmann,
Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer.
1994,
Pubmed Thiele,
Deciphering enzyme function using peptide arrays.
2011,
Pubmed Thompson,
Regulation of the p300 HAT domain via a novel activation loop.
2004,
Pubmed Vogel,
Insights into the regulation of protein abundance from proteomic and transcriptomic analyses.
2012,
Pubmed
